# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-SEC
PrimeC slowed disease progression by 43% (p=0.02) in pre-specified high-risk ALS patientsConsistent data across subgroups under...
Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consiste...
NeuroSense Therapeutics Ltd, a company developing novel treatments for severe neurodegenerative diseases, today announced it ha...
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neur...